Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. JCAP
JCAP logo

JCAP Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
19.620
Open
19.430
VWAP
19.35
Vol
173.73K
Mkt Cap
1.07B
Low
19.000
Amount
3.36M
EV/EBITDA(TTM)
7.60
Total Shares
55.33M
EV
2.45B
EV/OCF(TTM)
9.13
P/S(TTM)
2.67
Jefferson Capital, Inc. is an analytically driven purchaser and manager of charged-off and insolvency consumer accounts with operations primarily in the United States, Canada, the United Kingdom and Latin America. The Company purchases and services both secured and unsecured assets, and its client base includes creditors, banks, fintech origination platforms, telecommunications providers, credit card issuers and auto finance companies. The Company purchases portfolios of consumer receivables at deep discounts to face value and manages them by working with individuals as they repay their obligations and work toward financial recovery. Previously charged-off receivables include receivables subject to bankruptcy proceedings. The Company also provides debt servicing and other portfolio management services to credit originators for non-performing loans.
Show More

Events Timeline

(ET)
2026-03-12
16:40:00
Company Reports Q4 Revenue of $154.8M
select
2026-01-08 (ET)
2026-01-08
06:20:00
Jefferies and Keefe Bruyette Jointly Manage Offering
select
2026-01-05 (ET)
2026-01-05
19:00:00
Aeva Stock Rises 26.8% After Announcing 4D LiDAR Integration with NvidiaDrive Hyperion
select
2026-01-05
16:30:00
Jefferson Capital Plans to Offer 10M Shares in Secondary Offering
select
2026-01-05
16:20:00
Jefferson Capital files to sell 10M shares of common stock for holders
select

News

seekingalpha
9.5
03-13seekingalpha
Jefferson Capital Reports Record Q4 2025 Earnings and Strategic Developments
  • Record Financial Performance: Jefferson Capital reported a record revenue of $155 million for Q4 2025, reflecting a 30% year-over-year increase, while adjusted pretax income reached $51 million, showcasing the company's sustained growth driven by strong deployments and higher net yields.
  • Investment Deployment Growth: The company achieved total investment deployments of $381 million in the quarter, up 6% from Q4 2024, indicating an aggressive expansion strategy and confidence in future growth prospects.
  • Enhanced Legal Channel Efficiency: Despite court costs rising 86% year-over-year to $17.7 million, Jefferson Capital's efficient legal channel operations are expected to support higher recovery rates in the future, further strengthening its financial stability.
  • Optimistic Outlook: Management anticipates collecting $1.1 billion of its receivables over the next 12 months, emphasizing the company's strong positioning and ongoing market opportunities in the current macroeconomic environment.
seekingalpha
9.5
03-12seekingalpha
Jefferson Capital Reports Strong Q4 Earnings Beat
  • Strong Earnings Performance: Jefferson Capital reported a Q4 Non-GAAP EPS of $0.69, beating expectations by $0.03, indicating a sustained improvement in profitability that boosts investor confidence.
  • Significant Revenue Growth: The company achieved revenues of $154.8 million, reflecting a 30.1% year-over-year increase, surpassing market expectations by $0.89 million, which underscores robust business expansion and strong market demand, further solidifying its market position.
  • Stock Offering Plan: Jefferson Capital successfully priced a $205 million stock offering at $20.50 per share, which is expected to provide additional funding support for future growth and investments.
  • Share Repurchase Plan: The company's shareholders plan a secondary offering while also repurchasing shares, a move that not only helps enhance EPS but also demonstrates management's confidence in the company's future prospects.
Globenewswire
8.5
01-08Globenewswire
Jefferson Capital Prices 10M Share Offering at $20.50 Each
  • Offering Size: Jefferson Capital announced a public offering of 10 million shares at $20.50 each, potentially raising $205 million to strengthen its capital structure for future acquisitions and investments.
  • Additional Purchase Option: Underwriters have a 30-day option to purchase an additional 1.5 million shares, which, if exercised, would further increase total capital and enhance market demand and liquidity for the stock.
  • Share Repurchase Plan: Concurrently, Jefferson Capital will repurchase 3 million shares at the same price from underwriters, indicating confidence in its stock and potentially boosting earnings per share.
  • Underwriter Lineup: The offering is managed by notable financial institutions including Jefferies and Keefe, Bruyette & Woods, reflecting strong market interest and trust in the transaction.
Globenewswire
8.5
01-05Globenewswire
Jefferson Capital Plans to Offer 10 Million Shares in Secondary Offering
  • Stock Offering Plan: Jefferson Capital intends to sell 10 million shares of common stock in an underwritten secondary offering, which is expected to provide liquidity to existing shareholders and enhance market confidence.
  • Additional Purchase Option: Underwriters will have a 30-day option to purchase an additional 1.5 million shares, further increasing market participation and potentially enhancing stock liquidity.
  • Share Repurchase Plan: Jefferson Capital plans to concurrently repurchase 3 million shares of common stock at the price paid by underwriters to selling shareholders, which will reduce the number of shares outstanding and may enhance earnings per share.
  • Underwriter Lineup: The secondary offering is being managed by Jefferies and Keefe, Bruyette & Woods as joint-lead book-running managers, reflecting strong market confidence and support for the company.
Benzinga
8.5
2025-12-31Benzinga
Cybin Inc Launches $100 Million Equity Program, Shares Drop 6.6%
  • Stock Decline: Cybin Inc's shares fell 6.6% to $8.00 in pre-market trading following the announcement of a $100 million at-the-market equity program with Cantor Fitzgerald, which may undermine investor confidence and complicate future fundraising efforts.
  • Market Reaction: The drop in Cybin's stock price reflects investor concerns regarding the new financing plan, potentially impacting the company's capital operations and shareholder value moving forward.
  • Industry Impact: Concurrently, other biotech firms like Corcept Therapeutics and NovaBay Pharmaceuticals also experienced stock declines, indicating a cautious sentiment across the biotech sector that could affect the overall fundraising environment.
  • Investor Focus: The lukewarm market response to Cybin's financing initiative may prompt the company to reassess its capital structure and financing strategies to navigate current market challenges.
Benzinga
5.0
2025-12-31Benzinga
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
  • FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
  • Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
  • Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
  • Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Wall Street analysts forecast JCAP stock price to rise
4 Analyst Rating
Wall Street analysts forecast JCAP stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
26.00
Averages
27.25
High
29.00
Current: 0.000
sliders
Low
26.00
Averages
27.25
High
29.00
Raymond James
Outperform
downgrade
$25 -> $22
AI Analysis
2026-03-13
Reason
Raymond James
Price Target
$25 -> $22
AI Analysis
2026-03-13
downgrade
Outperform
Reason
Raymond James lowered the firm's price target on Jefferson Capital to $22 from $25 and keeps an Outperform rating on the shares. Despite reducing its price target, the firm continues to believe Jefferson's lower leverage, efficient collection model, heavy exposure to the U.S. market, which the firm believes is "currently more attractive," and recent acquisition of Blue Stem "position Jefferson Capital to outperform in the medium term."
Texas Capital
NULL
to
Buy
initiated
$28
2026-02-10
Reason
Texas Capital
Price Target
$28
2026-02-10
initiated
NULL
to
Buy
Reason
Texas Capital initiated coverage of Jefferson Capital with a Buy rating and $28 price target, which implies 29% total return when including the dividend. Jefferson is a technology enabled buyer and processor of charged-off, insolvency, and active consumer receivables, the analyst tells investors in a research note. The firm says the company has reported more consistent operating results relative to peers. It sees an attractive valuation given Jefferson's "high margin franchise."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for JCAP
Unlock Now

Valuation Metrics

The current forward P/E ratio for Jefferson Capital Inc (JCAP.O) is 7.99, compared to its 5-year average forward P/E of 6.70. For a more detailed relative valuation and DCF analysis to assess Jefferson Capital Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
6.70
Current PE
7.99
Overvalued PE
8.59
Undervalued PE
4.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
6.28
Current EV/EBITDA
6.89
Overvalued EV/EBITDA
8.00
Undervalued EV/EBITDA
4.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.67
Current PS
1.95
Overvalued PS
2.14
Undervalued PS
1.21

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks with strong buy
Intellectia · 9 candidates
Market Cap: >= 1000.00MDividend Yield Ttm: >= 1Analyst Consensus: Strong BuyWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20Annual Eps Yoy Growth: >= 15.0%Annual Revenue Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
RY logo
RY
Royal Bank of Canada
235.24B
NEM logo
NEM
Newmont Corporation
129.76B
AU logo
AU
Anglogold Ashanti PLC
51.18B
NLY logo
NLY
Annaly Capital Management Inc
16.28B
PR logo
PR
Permian Resources Corp
12.13B
BANC logo
BANC
Banc of California Inc
3.28B

Whales Holding JCAP

N
North Reef Capital Management LP
Holding
JCAP
-4.37%
3M Return
N
Nantahala Capital Management, LLC
Holding
JCAP
-15.55%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Jefferson Capital Inc (JCAP) stock price today?

The current price of JCAP is 19.43 USD — it has increased 0.67

What is Jefferson Capital Inc (JCAP)'s business?

Jefferson Capital, Inc. is an analytically driven purchaser and manager of charged-off and insolvency consumer accounts with operations primarily in the United States, Canada, the United Kingdom and Latin America. The Company purchases and services both secured and unsecured assets, and its client base includes creditors, banks, fintech origination platforms, telecommunications providers, credit card issuers and auto finance companies. The Company purchases portfolios of consumer receivables at deep discounts to face value and manages them by working with individuals as they repay their obligations and work toward financial recovery. Previously charged-off receivables include receivables subject to bankruptcy proceedings. The Company also provides debt servicing and other portfolio management services to credit originators for non-performing loans.

What is the price predicton of JCAP Stock?

Wall Street analysts forecast JCAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JCAP is27.25 USD with a low forecast of 26.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Jefferson Capital Inc (JCAP)'s revenue for the last quarter?

Jefferson Capital Inc revenue for the last quarter amounts to 101.55M USD, increased 20.94

What is Jefferson Capital Inc (JCAP)'s earnings per share (EPS) for the last quarter?

Jefferson Capital Inc. EPS for the last quarter amounts to 0.62 USD, increased 47.62

How many employees does Jefferson Capital Inc (JCAP). have?

Jefferson Capital Inc (JCAP) has 1120 emplpoyees as of March 25 2026.

What is Jefferson Capital Inc (JCAP) market cap?

Today JCAP has the market capitalization of 1.07B USD.